The Open University of Israel
Prof. Miriam C. Souroujon

Prof. Miriam C. Souroujon

Department of Natural Sciences

Updated: August 2013


 

Personal

Tel. (Office): 972-9-778-1758

Fax: 972-9-778-0661

E-mail: miriso@openu.ac.il

Date and place of birth: 15 November 1949, Israel
Marital Status: Married + 3

Back

Professional Education

1985-1987 Postdoctoral fellow at the Dept. of Hematology/Oncology, Tufts University, School of Medicine, Boston, MA
1985 Ph.D., Immunology, Dept. of Chemical Immunology, The Weizmann Institute of Science, Israel
1972 M.Sc. (cum laude), Microbiology, Tel-Aviv University, Israel
Back

Major Fields of Research

Back

Academic Appointments

2013 - Dean of Research
2009-2013 Member, Executive Committee, the Open University
2005-2009 Head, Research Authority, The Open University of Israel
1999-2003 Dean of Academic Studies, The Open University of Israel
2002-2003 Dean of Graduate Studies, The Open University of Israel
2001- Professor, The Open University of Israel
1987 - Visiting Scientist, Dept. of Immunology, The Weizmann Institute of Science, Rehovot, Israel
1997-1998 Visiting Professor, Dept. of Molecular Pharmacology, Stanford University, School of Medicine, CA
1993-2001 Associate Professor, The Open University of Israel
1987-1993 Senior Lecturer, The Open University of Israel
Back

Administrative Activities

2009-2013 Member, Executive Committee, the Open University
2009 - Head, committee for the recruitment of outstanding researchers
2006-2007 Member, committee for reassessing teaching at the Open University
2006-2007 Member, committee for reassessing the structure and organization of the academic activities
2006-2007 Head, Ad hoc committee for IP regulations at the Open University
2003 - Member, Appointments and Promotion Committee for lecturers and senior lecturers
2003-2007 Member, Appointments and Promotion Committee for associate and full professors
1995 - Member, Council of the Open University of Israel
1990-2000 Member, Academic Committee
1988 - Member, Academic Subcommittee for Natural and Life Sciences
1988 - Member, The Faculty Council
1996-1998 Head, Life Sciences Section in the Dept. of Natural Sciences
1995-1997 Member, Appointments and Promotion Committee for lecturers and senior lecturers
1996-1997 Member, Steering Committee for Marketing of Open University Books
1991-1994 Chair, Academic Subcommittee for Natural and Life Sciences
Back

Sponsored Research

Period Sponsoring Agency and Title of Research
2010-2013 Research grant from the European Commission: "Myasthenias, a group of immune mediated neurological diseases: from etiology to therapy" (FIGHT-MG)
2009-2011 Research grant from the American Muscular Dystrophy Association (MDA): "Suppression of myasthenia gravis by regulatory T cells: studies in EAMG"
2009-2011 Research grant from Association Francaise contre les Myopathies (AFM): "Involvement and therapeutic potential of regulatory T cells in myasthenia gravis: studies in EAMG"
2006-2009 Research grant from the European Commission: "Development of models to improve management of Myasthenia Gravis: From basic knowledge to clinical application" (MYASTAID)1
2007-2009 Research grant from the Israel Ministry of Health: "Novel immunotherapies for myasthenia gravis: studies in EAMG"
2006-2008 Research grants from the Association Française contre les Myopathies (AFM): "Immunomodulation of myasthenia gravis employing the rat model disease"
2004-2007 Research grant from the American Muscular Dystrophy Association (MDA): "Immunotherapy of experimental myasthenia gravis"
2001-2004 Research grant from the European Commission: “Innovative therapeutic strategies for the prototype autoimmune disease, myasthenia gravis”
2001-2004 Research grant from the European Commission: “Mechanisms of Myasthenia Gravis”1
2002-2004 Research grant from the American Muscular Dystrophy Association (MDA): "Immunotherapy of experimental myasthenia gravis"1
2001-2003 Grant from the Open University Research Authority: "Folding and trafficking of amyloid precursor protein; focus on presenilin"1
2000-2003 Research grants from the Association Francaise contre les Myopathies (AFM): "Antigen-specific treatment of myasthenia gravis"1
1999-2001 Research grants from the American Muscular Dystrophy Association (MDA): "Antigen-specific immunotherapy of experimental myasthenia gravis"1
1997-1998 Research grants from the American Muscular Dystrophy Association (MDA): "Recombinant fragments of AChR as modulators of myasthenia gravis"1
1994-1997 Research grants from the American Muscular Dystrophy Association (MDA): "Modulation of myasthenia gravis by epitopes and fragments of AChR"1
1999-2000 Grant from the Open University Research Authority (gishush): "Amyloid precursor protein, biosynthetic compartmentalization and generation of A-beta"2
1996-1999 Research grants from the Association Francaise contre les Myopathies (AFM): "Myasthenia gravis: regulation of gene expression, immunological specificity and modulation"1
1996-1997 Research grant from the Robert Koch-Minerva center for research in Autoimmune diseases. "Modulation of myasthenia gravis by acetylcholine receptor-derived recombinant fragments and selected epitopes"1
1994-1996 Research grants from the Association Franco-Israelienne pour la recherché scientifique et technologique (AFIRST): "Myasthenia gravis: regulation of gene expression, immunological specificity and modulation"1
1994-1996 Research grant from the Israeli Ministry of Health: "Diagnosis and modulation of myasthenia gravis by recombinant fragments and epitopes of the acetylcholine receptor"1
1993-1995 Research grants from the Association Francaise contre les Myopathies (AFM): "Recombinant human acetylcholine receptor and specific epitopes in the regulation and diagnosis of myasthenia gravis"1
1986-1987 Fellowship from the Lupus Foundation of America
1985-1986 Fellowship from the Rothschild Foundation

 
1 with Prof. Sara Fuchs, The Weizmann Institute of Science
2 with Prof. Drorit Neumann, Tel-Aviv University
Back

Membership in Professional Societies

2000 - Israel NeuroImmunology Society (member of the board since 2009)
1998 - The New York Academy of Sciences
1998 - Society for Neuroscience
1985 - Israel Immunological Society (member of the board 2006-2008)
Back

Patents

Back

Supervision of higher degrees

Yasmin Ohana Haim PhD., Tel-Aviv University (with Prof. D. Neumann)
S. H. Im PhD, The Weizmann Institute of Science (with Prof. S. Fuchs)
I. Levin M.Sc., Tel-Aviv University (with Dr. D. Neuman)
C. Bareket-Seraya M.Sc., Tel-Aviv University (with Dr. D. Neuman)
N. Rabin Ph.D., Tel-Aviv University (with Dr. D. Neuman)
T. Liron M.Sc. and PhD., Tel-Aviv University (with Prof. D. Neuman)
Back

Teaching Responsibilities and Development of Open University Courses

Back

List of Publications

Thesis and Dissertation

Degree Thesis title Supervisor
M.Sc. The influence of MER adjuvant and the structure of the carrier, on the immune response of guinea-pigs towards DNP Prof. Shlomo Ben-Ephraim
Ph.D. Monoclonal antibodies and their anti-idiotypes as tools for studying acetylcholine receptor and myasthenia gravis Prof. Sara Fuchs
Back

Articles in Refereed Journals

  1. S. Ben Efraim, M. Constantini-Souroujon and D. Weiss.
    Potentiation and modulation of the immune response of guinea-pigs to poorly immunogenic protein-hapten conjugates by pre-treatment with the MER fraction of attenuated tubercle bacilli. Cell. Immunol. 7, 370-379 (1973).
  2. M. Shinizky and M. Souroujon.
    Passive modulation of blood-group antigens. Proc. Natl. Acad. Sci. USA. 76, 4438-4440 (1979).
  3. M.C. Souroujon, D. Mochly-Rosen, A.S. Gordon and S. Fuchs.
    Interaction of monoclonal antibodies to Torpedo acetylcholine receptor with the receptor of skeletal muscle. Muscle & Nerve 6, 303-311 (1983).
  4. M. Schreiber, L. Fogelfeld, M.C. Souroujon, F. Kohen and S. Fuchs.
    Antibodies to spiroperidol and their anti-idiotypes as probes for studying dopamine receptors. Life Sci. 33, 1519-1526 (1983).
  5. S. Pizzighella, A.S. Gordon, M.C. Souroujon, D. Mochly-Rosen, A. Sharp and S. Fuchs.
    An Anti-acetylcholine receptor monoclonal antibody cross-reacts with phosvitin. FEBS Lett. 159, 246-250 (1983).
  6. M.C. Souroujon, S. Pizzighella, D. Mochly-Rosen and S. Fuchs.
    Antigenic specificity of acetylcholine receptor in developing muscle: Studies with monoclonal antibodies. J. Neuroimmunol. 8, 159-166 (1985).
  7. M.C. Souroujon, D. Barchan and S. Fuchs.
    Analysis and modulation of the immune response of mice to acetylcholine receptor by anti-idiotypes. Immunol. Lett. 9, 331-336 (1985).
  8. M.C. Souroujon, A.R. Pachner and S. Fuchs.
    The treatment of passively transferred experimental myasthenia with anti-idiotypic antibodies. Neurology 35, 622-625 (1986).
  9. M.C. Souroujon, D. Neumann, S. Pizzighella, A. Safran and S. Fuchs.
    Localization of a highly immunogenic region on the acetylcholine receptor a-subunit. Biochem. Biophys. Res. Commun. 135, 82-89 (1986).
  10. M.C. Souroujon, D. Neumann, S. Pizzighella, M. Fridkin and S. Fuchs.
    Mapping of the cAMP-dependent phosphorylation sites on the acetylcholine receptor. EMBO J. 5, 543-546 (1986).
  11. A.R. Pachner, M.C. Souroujon and S. Fuchs.
    Anti-idiotypic antibodies to anti-acetylcholine receptor antibody: Characterization by ELISA and immunoprecipitation assays. J. Neuroimmunol., 12, 205-214 (1986).
  12. M.C. Souroujon, M. White-Scharf, J. Andre-Schwartz, M. Gefter and R.S. Schwartz.
    Preferential autoantibody reactivity of the preimmune B-cell repertoire. J. Immunol. 140, 4173-4179 (1988).
  13. M.C. Souroujon, D.B. Rubinstein, R.S. Schwartz and K.J. Barrett.
    Polymorphisms in human H chain region genes from the VHIII gene family. J. Immunol. 143, 706-711 (1989).
  14. M.C. Souroujon, S. Carmon, A. Safran and S. Fuchs.
    Differences between embryonic and adult Torpedo acetylcholine receptor. FEBS. Lett. 288, 222-226 (1991).
  15. M.C. Souroujon, S. Carmon and S. Fuchs.
    Modulation of anti-acetylcholine receptor antibody specificities and of experimental autoimmune myasthenia gravis by synthetic peptides. Immunol. Lett. 34, 19-26 (1992).
  16. O. Asher, W.A. Kues, V. Witzemann, S.J. Tzartos, S. Fuchs and M.C. Souroujon.
    Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia. J. Immunol. 151, 6442-6450 (1993).
  17. O. Asher, S. Fuchs and M.C. Souroujon
    Acetylcholine receptor and myogenic factor gene expression in Torpedo embryonic development. NeuroReport 5, 1581-1584 (1994).
  18. D. Barchan, M. Balass, M.C. Souroujon, E. Katchalski-Katzir and S. Fuchs.
    Identification of epitopes within a highly immunogenic region of acetylcholine receptor by a phage epitope library. J. Immunol. 155, 4264-4269 (1995).
  19. D. Barchan, O. Asher, S.J. Tzartos, S. Fuchs and M.C. Souroujon.
    Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Eur. J. Immunol. 28, 616-624 (1998).
  20. M.C. Souroujon and D. Mochly-Rosen.
    Peptide modulators of protein-protein interactions in intracellular signaling; focus on protein kinase C. Nature Biotechnology 16, 919-924 (1998).
  21. G.W. Dorn, M.C. Souroujon, T. Liron, C-H, Chen, M.O. Gray, H.Z. Zhou, M. Csukai, G. Wu, J.N. Lorenz and D. Mochly-Rosen.
    Sustained in vivo cardiac protection by a rationally designed peptide that causes e protein kinase C translocation. Proc. Natl. Acad. Sci. USA 96, 12798-12803 (1999).
  22. D. Barchan, M.C. Souroujon, S-H. Im, C. Antozzi and S. Fuchs.
    Antigen-specific modulation of experimental myasthenia gravis: Nasal tolerization with recombinant fragments of the human acetylcholine receptor a-subunit. Proc. Natl. Acad. Sci. USA 96, 8086-8091 (1999).
  23. S-H. Im, D. Barchan, S. Fuchs and M.C. Souroujon.
    Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J. Clin. Invest. 104, 1723- 1728 (1999).
  24. S-H. Im, D. Barchan, M.C. Souroujon and S. Fuchs.
    Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis. J. Immunol. 165, 3599 - 3605 (2000).
  25. S-H. Im, D. Barchan, S. Fuchs and M.C. Souroujon.
    Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J. Neuroimmunol. 111, 161-168 (2000).
  26. S-H. Im, D. Barchan, P. K. Maiti, S. Fuchs and M.C. Souroujon.
    Blockade of CD40 ligand suppresses chronic experimental myasthenia by down regulation of Th1 differentiation and up-regulation of CTLA-4. J. Immunol. 166, 6893-6898 (2001).
  27. S-H. Im, D. Barchan, P. K. Maiti, L. Raveh, M.C. Souroujon and S. Fuchs.
    Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J .15, 2140-2148 (2001).
  28. S-H. Im, S-H. Kim, T. Azam, N. Venkatesh, C.A. Dinarello, S. Fuchs and M. C. Souroujon.
    Rat interleukin-18 Binding protein: cloning, expression, and characterization. J. Interferon & Cytokine Research. 22, 321-328 (2002).
  29. S-H. Im, D. Barchan, T. Feferman, L. Raveh, M.C. Souroujon and S. Fuchs.
    Protective molecular mimicry in experimental myasthenia gravis. J. Neuroimmunol. 126, 99-106 (2002).
  30. P. K. Maiti, S-H. Im, M. C. Souroujon and S. Fuchs.
    A monoclonal antibody specific for rat IL-18BP and its application in determining serum IL-18BP. Immunol. Lett. 85 :65-70 (2003).
  31. T. Feferman, S-H. Im, S. Fuchs and M.C. Souroujon.
    Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis. J. Neuroimmunol. 140, 153-158, (2003).
  32. M.C. Souroujon, L. Yao, H. Chen, G. Endemann, H. Khaner, V. Geeraert, D. Schechtman, A. S. Gordon, I. Diamond, and D. Mochly-Rosen.
    State-specific monoclonal antibodies identify an intermediate state in epsilon protein kinase C activation. J. Biol. Chem. 279, 17617-24 (2004).
  33. P.K. Maiti, T. Feferman, S-H. Im, M.C. Souroujon and S. Fuchs.
    Immunotherapy of rat myasthenia gravis by oral administration of a syngeneic recombinant acetylcholine receptor fragment. J. Neuroimmunol. 152, 112-120, 2004.
  34. T. Feferman, P.K. Maiti, S. Berrih-Aknin, J. Bismuth, J. Bidault, S. Fuchs and M.C. Souroujon.
    Overexpression of interferon-induced protein 10 (IP-10) and its receptor CXCR3 in myasthenia gravis. J. Immunol. 174, 5324-5331, 2005.
  35. S. Berrih-Aknin, S. Fuchs and M.C. Souroujon.
    Vaccines against Myasthenia Gravis. Expert Opin. Biol. Therapy 5, 983-995, 2005.
  36. R. Aricha, T. Feferman, M.C. Souroujon and S. Fuchs.
    Inhibition of phosphodiesterases by pentoxifyllin suppresses experimental autoimmune myasthenia gravis. FASEB J. 20, 374-376, 2006.
  37. K.Y. Zhu, T. Feferman, P.K. Maiti, M.C. Souroujon and S. Fuchs.
    Intravenous Immunoglobulin Suppresses Experimental Myasthenia Gravis: Immunological Mechanisms. J. Neuroimmunol. 176, 187- 197, 2006.
  38. T. Liron, C. Bareket-Seraya, M. Ish-Shalom, M.C. Souroujon and D. Neumann.
    Overexpression of Amyloid Precursor Protein Reduces Epsilon Protein Kinase C Levels. Neuroscience 146, 153-159, 2007.
  39. S. Fuchs, T. Feferman, R. Meidler, T. Brenner, O. Laub and M.C. Souroujon.
    The disease-specific arm of the therapeutic effect of IVIG in autoimmune diseases: Experimental autoimmune myasthenia gravis as a model. Isr. Med. Ass. J. 10, 58-60, 2008.
  40. R. Aricha, T. Feferman, S. Fuchs and M.C. Souroujon.
    Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J. Immunol. 180: 2132-2139, 2008.
  41. S. Fuchs, T. Feferman, R. Meidler, R. Margalit, C. Sicsic, N. Wang, K-Y. Zhu, T. Brenner, O. Laub and M.C. Souroujon.
    A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J. Neuroimmunol. 194, 89-96, 2008.
  42. R. TR. Menon, T. Feferman, R. Aricha, M.C. Souroujon and S. Fuchs.
    Suppression of experimental autoimmune myasthenia gravis by combination therapy; Pentoxifylline as a steroid-sparing agent. J. Neuroimmunol. 201-202, 128-135, 2008.
  43. H-J. Yi, C-S. Chae, J.-S. So, S. J. Tzartos, M.C. Souroujon, S. Fuchs and S-H. Im.
    Suppression of Experimental Myasthenia Gravis by a B-cell Epitope Free Recombinant Acetylcholine Receptor. Mol. Immunol. 46, 192-201, 2008.
  44. T. Feferman, R. Aricha, K. Mizrachi, E. Geron, R. Alon, M.C. Souroujon and S. Fuchs.
    Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-γ inducible protein 10 (IP-10) and its receptor CXCR3. J Neuroimmunol. 209, 87-95, 2009.
  45. K. Mizrachi, R. Aricha, T. Feferman, N. Kela-Madar, I. Mandel, T. Paperna, A. Miller, A. Ben-Nun, S. Berrih-Aknin, M.C. Souroujon and Sara Fuchs.
    Involvement of phosphodiesterases in autoimmune diseases. J. Neuroimmunol. J. 220, 43-51, 2010.
  46. T. Liron, T. Nahari, M.C. Souroujon and D. Neumann.
    Insertion of an NPVY sequence into the cytosolic domain of erythropoietin receptor selectively affects erythropoietin mediated signaling and function. Biochemical J. 427, 305-312, 2010.
  47. R. Aricha, T. Feferman, H. S. Scott, M.C. Souroujon, S. Berrih-Aknin and S. Fuchs.
    The susceptibility of Aire-/-mice to EAMG involves alterations in regulatory T cells. J. Autoimmunity 36, 16-24, 2011.
  48. R. Aricha, K. Mizrachi, S. Fuchs and M.C. Souroujon.
    Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J. Autoimmunity 36, 135-4, 2011.
  49. Berrih-Aknin, S and Souroujon M. C. Cutting edge in Myasthenia Gravis. Autoimmun Rev. 12, 861-2, 2013.
  50. S. Gertel-Lapter, K. Mizrachi, S. Berrih-Aknin, S. Fuchs and M.C. Souroujon. Impairment of regulatory T cells in experimental autoimmune myasthenia gravis. Autoimmunity Reviews. 12, 894–903, 2013.
  51. R. Aharoni, R. Aricha, R. Eilam, I. From, K. Mizrahi, R. Arnon, M.C. Souroujon and S. Fuchs. Age dependent course of EAE in Aire−/− mice. J. Autoimmun. [Epub ahead of print], 2013
Back

Articles in Refereed Books

  1. D. Mochly-Rosen, M.C. Souroujon, Z. Eshhar and S. Fuchs.
    Monoclonal antibodies to the nicotinic acetylcholine receptor. in "Monoclonal Antibodies to Neural Antigens", R. McKay, M.C. Raff and L.F. Reichardt, eds., Cold Spring Harbor Symposia, pp. 193-202 (1981).
  2. S. Fuchs, D. Bartfeld, D. Mochly-Rosen, M. Souroujon and C. Feingold.
    Acetylcholine receptor: Molecular dissection and monoclonal antibodies in the study of experimental myasthenia. Ann. N.Y. Acad. Sci. 377, 110-124 (1981).
  3. M.C. Souroujon, D. Mochly-Rosen, D. Bartfeld and S. Fuchs.
    Experimental autoimmune myasthenia gravis: Specificity of antibodies to acetylcholine receptor. In: Muscle Development: Molecular and Cellular Control, M.L. Pearson and H.F. Epstein, eds. Cold Spring Harbor Symposia, pp. 527-534 (1982).
  4. M.C. Souroujon, S. Pizzighella, D. Mochly-Rosen and S. Fuchs.
    Acetylcholine receptor in developing muscle studied by monoclonal antibodies. In: Developmental Processes in Normal and Diseased Muscle, H.M. Eppenberger and J.P. Perriard, eds., S. Karger, Basel, pp 63-67 (1984).
  5. S. Fuchs, M.C. Souroujon and D. Mochly-Rosen.
    Antibodies to the acetylcholine receptor. In: Monoclonal Antibodies to Receptors: Probes for Receptor Structure and Function. Receptors and Recognition, Series B, Vol. 17). M.F. Greaves ed. Chapman and Hall, pp. 165-199 (1984).
  6. S. Fuchs, M. Souroujon and S. Bogen.
    Regulation of the immune response to the acetylcholine receptor and of experimental myasthenia. In: Molecular Basis of Nerve Activity, J-P. Changeux, F. Hucho, A. Maelicke and E. Neumann, eds., W. de Gruyter, Berlin, pp. 493-504 (1985).
  7. M.C. Souroujon and S. Fuchs.
    Idiotypes and anti-idiotypes in experimental autoimmune myasthenia gravis. Ann. N.Y. Acad. Sci. 475, 81-93 (1986).
  8. S. Fuchs, D. Neumann, A. Safran, M.C. Souroujon, D. Barchan, M. Fridkin,, J.. Gershoni, R. Mantegazza and S. Pizzighella.
    Synthetic peptides and their antibodies in the analysis of the acetylcholine receptor. Ann. N.Y. Acad. Sci. 505, 256-271 (1987).
  9. M.C. Souroujon and S. Fuchs.
    Anti-idiotypic antibodies in the regulation of experimental autoimmune myasthenia gravis. Ann. N.Y. Acad. Sci. 505. 676-682 (1987).
  10. M.C. Souroujon and S. Fuchs.
    Anti-idiotypic antibodies in the sand treatment of experimental autoimmune myasthenia gravis. Methods in Enzymology. 178: "Antibodies, Antigens, and molecular mimicry". J.J. Langone, ed. Academic Press. pp. 434-448 (1989).
  11. M.C. Souroujon, S. Carmon and S. Fuchs.
    Regulation of experimental autoimmune myasthenia gravis by synthetic peptides of the acetylcholine receptor. Ann. N.Y. Acad. Sci. 681, 332-335 (1993).
  12. M.C. Souroujon and S. Fuchs.
    Experimental autoimmune myasthenia gravis. In: Immunological Methods Manual. (ed. I. Lefkovits), Academic Press, pp. 1763-1773 (1997).
  13. M.C. Souroujon, D. Barchan and S. Fuchs.
    Modulation of experimental autoimmune myasthenia gravis by recombinant fragments of the human acetylcholine receptor. Ann. N.Y. Acad. Sci. 841, 572-575 (1998).
  14. S. Fuchs, S-H. Im, D. Barchan and M.C. Souroujon.
    Antigen-specific therapy of experimental autoimmune myasthenia gravis: Mucosal tolerance with recombinant fragments of the human acetylcholine receptor. In: Myasthenia gravis: Disease mechanisms and immunointervention. P. Christadoss (Ed.). Narosa Publishing House, New Delhi. pp. 173-181 (2000).
  15. M.C. Souroujon, P. K. Maiti , T. Feferman, S-H Im, L. Raveh and S. Fuchs.
    Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors. Ann. N.Y. Acad. Sci. Sep; 998:533-6 (2003).
  16. T. Feferman, S-H. Im, S. Fuchs and M.C. Souroujon.
    Epitope spreading to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis. Ann. N.Y. Acad. Sci. Sep; 998:388-90 (2003).
  17. M.C. Souroujon, T. Feferman, P.K. Maiti, S.-H. Im, L. Raveh and S. Fuchs.
    Immunotherapy of myasthenia gravis: antigen-specific mucosal tolerance and antagonists of key cytokines and costimulatory factors. In I. Silman, H. Soreq, L. Anglister, D. Michaelson and A. Fisher (eds.), Cholinergic Mechanisms: function and dysfunction, pp. 241-244, Taylor & Francis Group UK (2004).
  18. T. Feferman, R. Aricha, P. K. Maiti, G. Clairac, M. Cuvelier, S. Berrih-Aknin, S. Fuchs and M.C. Souroujon.
    DNA microarrays analysis: new drug targets for myasthenia gravis. Proceedings of the 8th International Congress of Neuroimmunology (Medimond S.r.l.) pp. 163-166 (2006).
  19. T. Feferman, R. Aricha, R. Menon, M.C. Souroujon, S. Berrih-Aknin and S. Fuchs.
    DNA Microarray in search of new drug targets for Myasthenia Gravis. In Autoimmunity, Part C: The Mosaic of Autoimmunity. Ed: Y. Shoenfeld and M. E. Gershwin. Ann. N.Y. Acad. Sci. 1107, 111-117 (2007).
  20. S. Fuchs, T. Feferman, K.Y. Zhu, R. Meidler, R. Margalit, N. Wang, O. Laub and M.C. Souroujon.
    Suppression of experimental autoimmune myasthenia gravis (EAMG) by intravenous immunoglobulins (IVIG) and isolation of a disease-specific IgG fraction. In: "Autoimmunity, Part B: Novel Applications of Basic Research". Ed: M. E. Gershwin and Y. Shoenfeld. N.Y. Acad. Sci. 1110, 550-558 (2007).
  21. S. Fuchs, T. Feferman, R. Meidler, R. Margalit, C. Sicsic, T. Brenner, O. Laub and M.C. Souroujon.
    Immunosuppression of EAMG by IVIG is mediated by a disease-specific Anti-immunogobulin fraction. In: "Myasthenia Gravis and Related Disorders: 11th International Conference". Ed.H. J. Kaminski and R. J. Barohn. Ann. N.Y. Acad. Sci. 1132, 244-248 (2008).
  22. S. Fuchs, T. Feferman, T. Brenner and M.C. Souroujon.
    IVIg treatment in experimental autoimmune myasthenia gravis. In: Myasthenia Gravis: Disease Mechanisms and Immune intervention. Premkumar Christadoss, Ed. Linus publishing Inc., 411-422 (2010).
  23. M.C. Souroujon, T. Feferman, S. Berrih-Aknin and S. Fuchs.
    Chemokines and chemokine receptors in MG and EAMG. In: Myasthenia Gravis: Disease Mechanisms and Immune intervention. Premkumar Christadoss, Ed. Linus publishing Inc., 295-308 (2010).
  24. M.C. Souroujon, T. Brenner and S. Fuchs.
    Development of novel therapies for MG: studies in animal models. In: Autoimmunity of Myasthenia Gravis. Marc De Baets, Ed. Autoimmunity, Informa Healthcare, NY. Published online, 19 March, 2010.
  25. M. C. Souroujon, R. Aricha, T. Feferman, K. Mizrachi, D. Reuveni and Sara Fuchs.  Treg cell-based immunotherapies in experimental autoimmune myasthenia gravis. Ann. N.Y. Acad. Sci. 1274, 120- 126, 2012.
  26. R. Aricha, T. Feferman, S. Berrih-Aknin, S. Fuchs and M. C. Souroujon. Experimental MG in Aire KO mice - A link between Aire and Treg cells. Ann. N.Y. Acad. Sci. 1275, 10-126, 2012.
  27. Y. Ohana, T. Liron, S. Prutchi-Sagiv, M. Mittelman, M.C. Souroujon and D. Neumann. Erythropoietin – a hematopoietic hormone with emerging diverse activities.  In "Handbook of Biologically Active Peptides". Abba Kastin, Ed. Elsevier, Academic Press.. 1619-1626, 2013.
Back

Articles in Refereed Conference Proceedings

  1. S. Fuchs, D. Mochly-Rosen, M. Souroujon and Z. Eshhar
    Monoclonal antibodies against the nicotinic acetylcholine receptor. Abst. Cold Spring Harbor Workshop on Monoclonal Antibodies to Neural Antigens (1980).
  2. M.C. Souroujon, D. Mochly-Rosen and S. Fuchs
    Studies of muscle acetylcholine receptor by monoclonal antibodies. Abst. Ann. Meeting Israel Biochem. Soc., p. 5 (1981).
  3. M.C. Souroujon, D. Mochly-Rosen, I. Weiss and S. Fuchs
    Anti-idiotypes against a site-directed anti-acetylcholine receptor monoclonal antibody. Abst. 14th Ann. Meeting Israel Immunol. Soc., p. 70 (1982).
  4. M. Schreiber, M.C. Souroujon and S. Fuchs
    Anti-idiotypes against anti-a-bungarotoxin antibodies bind to the nicotinic acetylcholine receptor. Proc. Joint Meeting Israeli Soc. Life Sci., Abst. A171 (1983).
  5. M.C. Souroujon, S. Pizzighella, A.S. Gordon, D. Mochly-Rosen and S. Fuchs
    Antigenic specificity of acetylcholine receptor during muscle development. Proc. Joint Meeting Israeli Soc. Life Sci., Abst. B222 (1983).
  6. S. Bogen, M.C. Souroujon, E. Mozes and S. Fuchs
    A suppressor T cell hybridoma specific for the acetylcholine receptor. Abst. 5th Intern. Cong. Immunol., Kyoto (1983).
  7. M. Souroujon, D. Barchan and S. Fuchs
    A neuromuscular block induced in chickens by an anti-acetylcholine receptor monoclonal antibody and reversed by specific anti-idiotypes. The 15th Annual Meeting of the Israel Immunological Society. p. 51 (1984).
  8. S. Fuchs, M.C. Souroujon, D. Neumann and S. Pizzighella
    Specific antibodies to the cAMP-dependent phosphorylation sites in the acetylcholine receptor. Proceedings, 15th Annual Meeting of the Society for Neuroscience, p93 (1985).
  9. D. Neumann, S. Pizzighella, M.C. Souroujon, A. Safran and S. Fuchs
    Species specific anti-acetylcholine receptor antibodies elicited by synthetic peptides. Abst. Proc. 7th European Immunology Meeting, Jerusalem, p. 207 (1985).
  10. S. Fuchs, M.C. Souroujon and D. Barchan
    Idiotypes and anti-idiotypes in the regulation of experimental autoimmune myasthenia gravis. Abst. Proc. 7th European Immunology Meeting, Jerusalem, p. 64 (1985).
  11. M.C. Souroujon, D. Neumann, A. Safran, S. Pizzighella and S. Fuchs
    Phosphorylation of the acetylcholine receptor: Analysis by antibodies to synthetic peptides. Abst. Proc. 7th European Immunology Meeting, Jerusalem, p. 166 (1985).
  12. M.E. White-Scharf, M. Souroujon, J. Andre-Schwartz, R.S. Schwartz and M.L. Gefter
     Specificity of the germline-encoded preimmune B cell repertoire. Symposia Proceedings of the UCLA meeting on "B Cell Development" (1988).
  13. D. Neumann, D. Barchan, M. Horowitz, M. Souroujon, E. Kochva and S. Fuchs
    Cloning of genomic sequences encoding snake AChR a-subunit. Abst. NATO advanced research workshop on "Nicotinic acetylcholine receptors in the nervous system". Venice, Italy (1988).
  14. D. Neumann, D. Barchan, M. Horowitz, M. Souroujon, E. Kochva, and S. Fuchs
    Cloning of genomic sequences encoding snake acetylcholine receptor.
  15. M.C. Souroujon, M.E. White-Scharf, J. Andre-Schwartz, M.L. Gefter and R.S. Schwartz
    Possible mechanisms for autoimmunity in view of the germline B cell repertoire. Annual meeting of the Israel Immunological Society. Isr. J. Med. Sci. 25, 174 (1989).
  16. M.C. Souroujon, S. Carmon, A. Safran and S. Fuchs
    Differences between the adult and embryonic g-subunit of Torpedo acetylcholine receptor. Abst. Society for Neuroscience 16, 683 (1990).
  17. M.C. Souroujon, S. Carmon and S. Fuchs
    Modulation of experimental autoimmune myasthenia gravis by acetylcholine receptor-derived synthetic peptides. J. Autoimmunity 4, XXIX (1991).
  18. M.C. Souroujon, S. Carmon and S. Fuchs
    Synthetic peptides of the acetylcholine receptor as regulators of anti-acetylcholine receptor response. J. Neuroimmunol. Suppl. 1, 117 (1991).
  19. O. Asher, W.A. Kues, V. Witzemann, S.J. Tzartos, S. Fuchs and M.C .Souroujon
    Acetylcholine receptor gene expression in experimental autoimmune myasthenia gravis passively transferred by monoclonal antibodies. Annual meeting of the Israel Immunological Society. Isr. J. Med. Sci. (1992).
  20. M. Balass, D. Barchan, M.C. Souroujon, E. Katchalski-Katzir and S. Fuchs
    Acetylcholine receptor epitopes associated with myasthenia gravis and identified by a phage-epitope library. Abst. Annual meeting of the Israel Immunological Society, Jerusalem (1994).
  21. O. Asher, W.A. Kues, V. Witzemann, S.J. Tzartos, S. Fuchs and M.C. Souroujon
    Acetylcholine receptor gene expression in experimental autoimmune myasthenia gravis passively transferred by monoclonal antibodies. Annual meeting of the Israel Immunological Society. Isr. J. Med. Sci. (1994).
  22. O. Asher, S. Fuchs and M.C. Souroujon
    Acetylcholine receptor gene expression in passively transferred experimental autoimmune myasthenia Gravis. Abst. Annual meeting of the Israel Society for Biochemistry and Molecular Biology, Israel (1994).
  23. M. Balass, D. Barchan, M.C. Souroujon, E. Katchalski-Katzir and S. Fuchs
    Conformation-dependent and sequential epitopes of AChR identified by a phage-epitope library. Abst. Euromyasthenia IV meeting. Neuromuscular Disorders 4, 535 (1994).
  24. S. Fuchs, O. Asher and M.C. Souroujon
    Acetylcholine receptor gene expression in experimental models of myasthenia gravis. Abst. Euromyasthenia IV meeting. Neuromuscular Disorders 4, 535 (1994).
  25. O. Asher, S. Fuchs, and M.C. Souroujon
    Acetylcholine receptor gene expression in Torpedo electric organ and skeletal muscle during embryonic development. Abst. Euromyasthenia IV meeting. Neuromuscular Disorders 4, 535 (1994).
  26. O. Asher, S. Fuchs, and M.C. Souroujon
    Developmental changes of acetylcholine receptor gene expression in Torpedo electric organ and skeletal muscle. Abst. Meeting on "The cholinergic synapse: structure, function and regulation. Baltimore, USA (1994).
  27. D. Barchan, M. Balass, M.C. Souroujon, E. Kachalski-Katzir, and S. Fuchs
    Epitopes within a highly immunogenic region of acetylcholine receptor identified by a phage epitope library. Abst. Meeting on "The cholinergic synapse: structure, function and regulation. Baltimore, USA (1994).
  28. O. Asher, S. Fuchs, and M.C. Souroujon
    Gene expression of acetylcholine receptor in Torpedo during embryonic development. 3rd Meeting of the Israeli Society for Neuroscience Eilat (1994).
  29. D. Barchan, O. Asher, S. Fuchs and M.C. Souroujon
    Modulation of the autoimmune response to acetylcholine receptor in experimental autoimmune myasthenia gravis by recombinant fragments of the receptor. Abst. Meeting of the Israel Immunological Society, Tel-Aviv (1995).
  30. M.C. Souroujon and S. Fuchs
    Selected epitopes for the analysis and modulation of the autoimmune response to acetylcholine receptor in myasthenia gravis. Abst. Meeting of AFIRST- Association Franco-Israelienne pour la Recherche Scientifique et Technologique, Jerusalem (1995).
  31. D. Barchan, O. Asher, S. Fuchs and M.C. Souroujon
    Modulation of experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Abst. Meeting of The Association Francaise contre les myopathies (AFM), Versailles (1996).
  32. M.C. Souroujon, D. Barchan, O. Asher, S. Berrih-Aknin and S. Fuchs
    Myasthenia gravis: Regulation of gene expression, immunological specificity and modulation. Abst. Meeting of AFIRST - Association Franco-Israelienne pour la Recherche Scientifique et Technologique, Albi, France (1996).
  33. S-H. Im, D. Barchan, M.C. Souroujon, and S. Fuchs
    Prevention of experimental autoimmune myasthenia gravis by oral administration of recombinant fragments of the human acetylcholine receptor a-subunit. Abst. Annual Meeting of the Israel Immunological Society (1998).
  34. D. Barchan, M.C. Souroujon, S-H. Im, C. Antozzi and S. Fuchs
    Antigen-specific immunotherapy of experimental autoimmune myasthenia gravis by nasal administration of recombinant fragments of the human acetylcholine receptor a-subunit. Abst. Annual Meeting of the Israel Immunological Society (1998).
  35. S. Fuchs, D. Barchan , S-H. Im and M.C. Souroujon
    Antigen-specific immunomodulation of experimental autoimmune myasthenia gravis. Abst. Pasteur-Weitzman Symposium (1998).
  36. S. Fuchs, D. Barchan, S-H. Im and M.C. Souroujon
    Antigen-specific immunotherapy of experimental myasthenia gravis: implications for human myasthenia gravis. Abst. IX International Congress on Neuromuscular Diseases, Adelaide, Australia (1998).
  37. S. Fuchs, S-H. Im, D. Barchan and M.C. Souroujon
    Antigen-specific therapy of experimental autoimmune myasthenia gravis. Abst. 10th International Congress of Immunology. New Delhi, India (1998).
  38. M.C. Souroujon, D. Barchan, S-H. Im and S. Fuchs
    Antigen-specific immunotherapy of experimental myasthenia gravis by fragments of the acetylcholine receptor. Abst. Soc. NeuroSci. (1998).
  39. S-H. Im, D. Barchan, S. Fuchs and M.C. Souroujon
    Tolerance in EAMG by AChR recombinant fragments; Role of conformation. Abst. 2nd International Congress on Autoimmunity, Tel-Aviv (1999).
  40. M.C. Souroujon, S-H. Im, D. Barchan, and S. Fuchs
    Antigen-specific treatment for experimental autoimmune myasthenia gravis: induction of mucosal tolerance by recombinant fragments of the human acetylcholine receptor. Abst. 2nd International Congress on Autoimmunity, Tel-Aviv (1999).
  41. S-H Im, D. Barchan, S. Fuchs and M.C. Souroujon
    Role of tolerogen conformation for the induction of oral tolerance in experimental autoimmune myasthenia gravis. Neurojunction meeting, Sportilia, Italy (1999).
  42. Levine, K. Kosik, M. Souroujon and D. Neumann
    Amyloid precursor protein, association with molecular chaperones in course of biosynthesis and generation of A-beta. Abst. Research Fair, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv (1999).
  43. M.C. Souroujon, S-H. Im, D. Barchan and S. Fuchs
    Oral tolerance induction by recombinant AChR fragments. Myology 2000 meeting, Nice, France (2000).
  44. S.-H. Im, D. Barchan, P.M. Maiti, M.C. Souroujon and S. Fuchs
    Cytokines and costimulatory factors for immunomodulation of experimental myasthenia gravis. Neuroscience Israeli Society, Eilat (2000).
  45. M.C. Souroujon, S-H. Im, D. Barchanand and S. Fuchs
    Mucosal tolerance as a therapeutic modality for experimental myasthenia gravis: Role of tolerogen conformation. Meeting of the Myasthenia Gravis Foundation of America (MGFA), Boston (2000).
  46. S.-H. Im, D. Barchan, P.K. Maiti, S. Fuchs and M.C. Souroujon
    The role of cytokines and costimulatory factors in immunomodulation of experimental myasthenia gravis. Abst. 30th Annual Meeting of the Israel Immunological Society, Rehovot (February, 2001).
  47. S.-H. Im, D. Barchan, T. Feferman, L, Raveh, M.C. Souroujon and S. Fuchs
    Protective molecular mimicry in experimental myasthenia gravis. Abst. 30th Annual Meeting of the Israel Immunological Society, Rehovot (2001).
  48. Levin, I., M. Ayalon-Sofer, K. Kosik, M. Souroujon and D. Neumann
    Involvement of molecular chaperones in intracellular metabolism of the amyloid precursor protein. Abst. EuroConference and EMBO workshop on “Mechanisms and cellular Functions of molecular chaperones. Barcelona, Spain (2001).
  49. M.C. Souroujon, S-H. Im, D. Barchan, L, Raveh, P.K. Maiti and S. Fuchs.
    Modulation of experimental autoimmune myasthenia gravis by interference with cytokine networks and costimulatory signaling to augment the therapeutic effect of antigen-specific mucosal tolerance. J. Neuroimmunology , 118:160, 2001. Abstracts of the International Society of Neuroimmunology Sixth International Congress. Edinburgh, Scotland (2001).
  50. T. Feferman, S-H. Im, S. Fuchs and M.C. Souroujon
    Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis. Abst. 31st Annual Meeting of the Israel Immunological Society, Tel Aviv (March, 2002).
  51. P.K. Maiti, T. Feferman, S-H. Im, M.C. Souroujon, and S. Fuchs
    A syngeneic acetylcholine receptor fragment suppresses experimental autoimmune myasthenia gravis through a shift fro Th1 to Th2 immune response.
    Abst. 31st Annual Meeting of the Israel Immunological Society, Tel Aviv (2002).
  52. M.C. Souroujon, S-H Im, P. Maiti, T. Feferman and S. Fuchs
    Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors. Abst. 2nd Annual Meeting of the Israel NeuroImmunology Society. Maale Hachamisha (2002).
  53. M.C. Souroujon, S-H Im, S. Fuchs.
    Immunotherapy of myasthenia gravis: antigen-specific mucosal tolerance and antagonists of key cytokines and costimulatory factors. Abst. XIth International Symposium on Cholinergic Mechanisms - Function and Dysfunction. St. Morits, Switzerland (2002).
  54. P.K. Maiti, T. Feferman, S-H I1, M.C. Souroujon and S. Fuchs
    Immunosuppression of experimental autoimmune myasthenia gravis by a syngeneic recombinant acetylcholine receptor fragment. Xth International Conference on Myasthenia Gravis and Related Disorders. Miami, FL (2002).
  55. T. Feferman, S-H Im, S. Fuchs and M.C. Souroujon
    Epitope spreading to hidden cytoplasmic regions of the acetylcholine receptor in experimental autoimmune myasthenia gravis. Xth International Conference on Myasthenia Gravis and Related Disorders. Miami, FL (2002).
  56. M.C. Souroujon, S-H Im, P. Maiti, T. Feferman and S. Fuchs
    Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors. Xth International Conference on Myasthenia Gravis and Related Disorders. Miami, FL (2002).
  57. T. Feferman, P.K. Maiti, S. Fuchs and M. Souroujon
    New genes involved in lymphocyte trafficking in experimental autoimmune myasthenia gravis. Abst. 3nd Annual Meeting of the Israel NeuroImmunology Society. Tel-Aviv (2003).
  58. R. Aricha, T. Feferman, P.K. Maiti, N.S. Wang, M. Souroujon and S. Fuchs
    Immunotherapy of experimental myasthenia gravis by Pentoxifylline, a general phosphodiesterase inhibitor. Abst. 3nd Annual Meeting of the Israel NeuroImmunology Society. Tel-Aviv (2003).
  59. K.Y. Zhu, T. Feferman, P.K. Maiti, M.C. Souroujon and S. Fuchs
    Suppression of experimental autoimmune myasthenia gravis by normal human immunoglobulins (IVIG). Abst. 32nd Annual Meeting of the Israel Immunological Society, Haifa (February, 2003).
  60. P.K. Maiti, T. Feferman, R. Shelly, M.C. Souroujon and S. Fuchs
    Identification of new genes involved in experimental autoimmune myasthenia gravis. Abst. 31st Annual Meeting of the Israel Immunological Society, Haifa (February, 2003).
  61. C. Bareket, M. Reyna, , M.C. Souroujon, D. Mochly-Rosen and D. Neumann
    Overexpression of amyloid precursor protein modulates protein kinase C levels. Abst. Research Fair, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv (April, 2003).
  62. M.C. Souroujon, T. Feferman, S-H. Im and S. Fuchs
    Epitope spreading to hidden cytoplasmic regions of the acetylcholine receptor in EAMG. European Myasthenia Gravis Network – Mid-Term meeting, Paris (May, 2003).
  63. M.C. Souroujon, P.K. Maiti, T. Feferman, R.Shely and S. Fuchs
    Identification of new genes involved in experimental autoimmune myasthenia gravis. European Myasthenia Gravis Network – Mid-Term meeting, Paris (May, 2003).
  64. S. Fuchs, K-Y. Zhu, P.K. Maiti, T. Feferman, S-H. Im and M.C. Souroujon
    Therapies for EAMG: IVIg and mucosal tolerance by a syngeneic AChR fragment. AFM-Inserm Myasthenia Gravis meeting,.Paris (May, 2003).
  65. T. Feferman, P. K. Maiti, S. Fuchs and M.C. Souroujon
    New genes - new targets in experimental autoimmune myasthenia gravis therapy. Abst. 32nd Annual Meeting of the Israel Immunological Society, Bar-Ilan (February, 2004).
  66. R. Aricha, T. Feferman, P.K. Maiti, N.S. Wang, M.C. Souroujon and S. Fuchs
    Pentoxifylline, a general phosphodiesterase inhibitor, suppresses experimental myasthenia gravis. Abst. 32nd Annual Meeting of the Israel Immunological Society, Bar-Ilan (February, 2004).
  67. C. Bareket Seraya, M., Reyna, N. Rabin, M.C. Souroujon, D. Mochly-Rosen and D. Neumann
    Protein kinase C epsilon levels are modulated by overexpression of amyloid precursor protein. Abst. Research Fair, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv (April, 2004).
  68. R. Aricha, T. Feferman, P.K. Maiti, N. S. Wang, M.C. Souroujon and S. Fuchs
    Inhibition of phosphodiesterase by Pentoxifylline suppresses autoimmune experimental myasthenia gravis. European Myasthenia Gravis Network – Mid-Term meeting. Athens, April, 2004.
  69. T. Feferman, P. K. Maiti, S. Berrih-Aknin, J. Bismuth, S. Fuchs and M.C. Souroujon
    New genes - new targets in autoimmune myasthenia gravis. 12th International Congress of Immunology and 4th annual Conference of FOCIS, Montreal, Canada (July, 2004).
  70. R. Aricha, T. Feferman, P.K. Maiti, N.S. Wang, M.C. Souroujon and S. Fuchs
    Inhibition of phosphodiesterase by Pentoxyfillyn suppresses experimental autoimmune myasthenia gravis. 12th International Congress of Immunology and 4th annual Conference of FOCIS, Montreal, Canada (July, 2004).
  71. M. Souroujon, T. Feferman, R. Aricha, P.K. Maiti, S. Berrih-Aknin and S. Fuchs
    New Genes - new targets for therapy of myasthenia gravis. 7th International congress of Neuroimmunology, Venice, Italy, September (2004).
  72. T. Feferman, G. Clairac, S. Fuchs, M. Souroujon and S. Berrih-Aknin
    Data mining and comparison of the muscle transcriptome in myasthenia gravis. Proceedings of "Myology 2005", Nantes, France (May, 2005).
  73. R. Aricha, T. Feferman, M. Souroujon and S. Fuchs
    Inhibition of phosphodiesterase by pentoxifyllin suppresses experimental autoimmune myasthenia gravis. Proceedings of "Myology 2005", Nantes, France (May, 2005).
  74. T. Feferman, P.K. Maiti, S. Berrih-Aknin, J. Bismuth, J. Bidault, S. Fuchs and M. Souroujon
    Interferon-induced protein 10 (IP-10) and its receptor CXCR3 are overexpressed in myasthenia gravis: new targets for immunotherapy. Proceedings of "Myology 2005", Nantes, France (May, 2005).
  75. T. Feferman, G. Clairac, S. Fuchs, M. Souroujon and S. Berrih-Aknin
    Data mining and comparison of the muscle transcriptome in myasthenia gravis. Abst. 5th Annual Meeting of the Israel NeuroImmunology Society, Tel-Aviv (2005).
  76. R. Aricha, T. Feferman, M. Souroujon and S. Fuchs
    Inhibition of phosphodiesterase by pentoxifyllin suppresses experimental autoimmune myasthenia gravis. Abst. 5th Annual Meeting of the Israel NeuroImmunology Society, Tel-Aviv (2005).
  77. T. Feferman, P.K. Maiti, S. Berrih-Aknin, J. Bismuth, J. Bidault, S. Fuchs and M. Souroujon
    Interferon-induced protein 10 (IP-10) and its receptor CXCR3 are overexpressed in myasthenia gravis: new targets for immunotherapy. Abst. 5th Annual Meeting of the Israel NeuroImmunology Society, Tel-Aviv (2005).
  78. T. Feferman, R. Aricha, P. K. Maiti, G. Clairac, M.Cuvelier, S. Berrih-Aknin , S. Fuchs and M. Souroujon
    DNA microarrays analysis in search of new drug targets for myasthenia gravis. Abst. 35th Annual meeting of the Israel immunological Society, Jerusalem (February, 2006).
  79. S. Fuchs , T. Feferman, R. Meidler, K.Y. Zhu, R. Margalit, N. Wang , O. Laub and M.C. Souroujon.
    A disease-specific anti-IgG fraction isolated from pooled human IgG (IVIG) suppresses experimental myasthenia gravis (EAMG). International congress of Neuroimmunology, Nagoya, Japan (September, 2006).
  80. T. Feferman, R. Aricha, P. K. Maiti, G. Clairac, M. Cuvelier, S. Berrih-Aknin, S. Fuchs and M.C. Souroujon
    DNA microarrays analysis: new drug targets for myasthenia gravis. Proceedings of the 8th International Congress of Neuroimmunology (Medimond S.r.l.) pp. 163-166 (2006).
  81. S. Fuchs, T. Feferman, K.Y. Zhu, R. Meidler, R. Margalit, N.Wang, O. Laub and M.C. Souroujon
    A disease-specific fraction isolated from pooled human IgG (IVIG) suppresses experimental myasthenia gravis. 5th International congress on autoimmunity, Sorrento, Italy (November, 2006)
  82. M.C. Souroujon, T. Feferman, R. Aricha, S. Berrih-Aknin, R. Menon and S. Fuchs
    The therapeutic potential of new drug targets for myasthenia gravis revealed by DNA microarray. 5th International congress on autoimmunity, Sorrento, Italy (November, 2006).
  83. R. Aricha, T. Feferman, M.C. Souroujon and S. Fuchs
    Regulatory T cells generated ex vivo as an approach for immunotherapy of EAMG.Abst. 36th Annual meeting of the Israel Immunological Society (February, 2007).
  84. R. Menon, T. Feferman, R. Aricha, M.C. Souroujon and S. Fuchs
    Suppression of EAMG by combined treatment with solumedrol and pentoxifylline at suboptimal doses. Abst. NYAS MG Conference, Chicago (May, 2007).
  85. S. Fuchs, T. Feferman, K.Y. Zhu, R. Meidler, R. Margalit, O. Laub and M.C. Souroujon
    Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction. Abst. NYAS MG Conference, Chicago (May 2007).
  86. T. Feferman, R. Aricha, P.K. Maiti, K. Mizrahi, S. Berrih-Aknin, S. Fuchs and M.C. Souroujon
    The chemokine IP-10/CXCR3 pathway is involved in the pathogenesis of myasthenia gravis. Abst. NYAS MG Conference, Chicago (May 2007).
  87. T. Feferman, M. Cuvelier, D. Yaffee, O. Fuchs, S. Fuchs, M.C. Souroujon and S. Berrih-Aknin
    Muscle gene expression in myasthenia gravis. Abst. NYAS MG Conference, Chicago (May, 2007).
  88. R. Aricha, T. Feferman, M.C. Souroujon and S. Fuchs
    Regulatory T cells generated ex vivo as an approach for immunotherapy of myasthenia gravis. Abst. NYAS MG Conference, Chicago (May, 2007).
  89. R. Aricha, T. Feferman, R. Menon, M.C. Souroujon and S. Fuchs
    Suppression of experimental autoimmune myasthenia gravis by combined treatment with solumedrol and pentoxifylline at suboptimal doses. Abst. Annual Meeting of the Israel NeuroImmunology Society, Tel-Aviv (2007).
  90. M. Souroujon, R. Aricha, T. Feferman and S. Fuchs
    In search of improved treatments for myasthenia gravis: studies in an experimental model of the disease. Abst. Annual Meeting of the Israel NeuroImmunology Society, Tel-Aviv (2007).
  91. R. Aricha, T. Feferman, M.C. Souroujon and S. Fuchs
    Regulatory T cells generated ex vivo as an approach for immunotherapy of myasthenia gravis. Abst. Annual Meeting of the Israel NeuroImmunology Society, Tel-Aviv (2007).
  92. R. Aricha, T. Feferman, M.C. Souroujon and S. Fuchs
    Ex vivo generated regulatory T cells as an approach for immunotherapy of experimental autoimmune myasthenia gravis. Abst. 1std annual meeting, WIRM, Davos, Switzerland (April, 2007).
  93. T. Liron, T. Nahari, M.C. Souroujon and D. Neumann
    A transplanted NPVY sequence in the cytosolic domain of the erythropoietin receptor enhances activation of AKT and ERK1/2 but not of STAT5. Abst. Gordon Conference on Growth Factors and Signaling, Oxford, England (August, 2008).
  94. R. Aricha, T. Feferman, H. Scott, M.C. Souroujon, S. Berrih-Aknin and S. Fuchs
    The susceptibility of Aire -/- mice to EAMG involves alteration in regulatory T cells. Abst. 38th Annual meeting of the Israel Immunological Society (February, 2009).
  95. K. Mizrachi, R. Aricha, T. Feferman, N. Kela-Madar, I. Mandel, T. Paperna, A.Miller, A. Ben-Nun, S. Berrih-Aknin, M.C. Souroujon and S. Fuchs
    Overexpression of phosphodiesterases in autoimmune diseases. Abst. 38th Annual meeting of the Israel Immunological Society (February, 2009).
  96. T. Feferman, R. Aricha, K. Mizrachi, E. Geron, R. Alon, O. Eizenberg, A. Peled, M.C. Souroujon and S. Fuchs
    Chemokines and their receptors as potential targets for the treatment of myasthenia gravis. Abst. 38th Annual meeting of the Israel Immunological Society (February, 2009).
  97. M.C. Souroujon, R. Aricha, T. Feferman, H. Scott, S. Berrih-Aknin and S. Fuchs
    Regulatory T cells and AIRE in myasthenia gravis. Abst. 10th annual meeting of the Israel Neuroimmunology Society. Tel-Aviv (April, 2009).
  98. R. Aricha, K. Mizrachi, S. Fuchs and M.C. Souroujon
    Blocking of IL-6 suppresses autoimmune myasthenia gravis by inhibition of Th17 responses. Abst. 39th Annual meeting of the Israel Immunological Society (February, 2010).
  99. R. Aricha, K. Mizrachi, S. Fuchs and M.C. Souroujon
    Treatment by anti-IL-6 suppresses experimental autoimmune myasthenia gravis by shifting the balance between Th17 and Treg cells. Abst. 11th Annual meeting of the Israel Neuroimmunology Society, Tel-Aviv (April, 2010).
  100. T. Liron, M.C. Souroujon and D. Neumann
    Rational design of a novel Erythropoietin-Receptor peptide antagonist. ESF Research Conference on Molecular Perspectives on Protein-Protein Interactions, Sant Feliu de Guixols, Spain (14-19 November, 2010).
  101. M.C. Souroujon, R. Aricha, K. Mizrachi and S. Fuchs
    Experimental autoimmune myasthenia gravis is suppressed by anti-IL-6 treatment which shifts the balance between Th17 and Treg cells. XX AINI Congress, Stresa, Italy (30 September - 3 October, 2010).
  102. T. Liron, M.C. Souroujon and D. Neumann
    Rational design of a novel Erythropoietin-Receptor peptide antagonist. Abst. XXXIII World Congress of the International Society of Hematology, Jerusalem, Israel (October 10-13, 2010).
  103. S. Gertel, K. Mizrachi, S. Fuchs . Functional impairment of regulatory T cells in experimental autoimmune myasthenia gravis. Abst. 12th Annual meeting of the Israel Neuroimmunology Society. Jerusalem, April, 2011.
  104. M.C. Souroujon. Regulatory T cells in experimental myasthenia gravis and their link to AIRE. 2nd French-Israeli workshop on regulatory T cells, Tolerance & Immunotherapy, Mishkenot Shaananim, Jerusalem, 31 October -1 November.  2011.
  105. M. C. Souroujon, R. Aricha, S. Gertel, T. Feferman, D. Reuveny, S. Berrih-Aknin and S. Fuchs. Involvement of Treg cells and Aire in the pathogenesis of myasthenia gravis studied in experimental models. The 8th International Congress on Autoimmunity, Granada, Spain, 9-13 May, 2012.
  106. M. C. Souroujon, R. Aricha, S, D. Reuveni, S. Berrih-Aknin, K. Mizrachi and S. Fuchs. Regulatory T cells in experimental autoimmune MG. 12th International Conference on Myasthenia Gravis and Related Disorders. NYC, May 21-23, 2012.
  107. D. Reuveni, S. Gertel, R. Aricha, D. Neumann, M. Mittleman, S. Fuchs and M. C. Souroujon. Erythropoietin ameliorates experimental MG. 12th International Conference on Myasthenia Gravis and Related Disorders. NYC, May 21-23, 2012.
  108. R. Aricha, R. Aharoni, M. C. Souroujon, S. Berrih-Aknin and S. Fuchs. Experimental MG in Aire KO mice- A link between Aire and Treg cells.  12th International Conference on Myasthenia Gravis and Related Disorders. NYC, May 21-23, 2012.
  109. S. Hiram-Bab, T. Liron, M.C. Souroujon, M. Eisenstein. and D. Neumann. Novel Erythropoietin-Receptor peptide antagonists. 9th International Lübeck Conference on the Pathophysiology and Pharmacology of Erythropoietin and other Hemopoietic Growth Factors. Lübeck, Germany, 13- 15 July,.2012.
  110. N. Deshet-Unger, Y. Ohana, S. Hiram-Bab, M, Gassmann, M, Mittelman, M. C.  Souroujon and D. Neumann. Erythropoietin as an anti-neoplastic agent: Characterization of erythoropoietin driven responses in the 5T33 multiple myeloma murine model. FASEB meeting on "Biology of the Immune system", Colorado, USA, June 24, 2012.
  111. R. Aricha, R. Aharoni, M.C. Souroujon, S. Berrih-Aknin, S. Fuchs. Autoimmunity in Aire-/- mice- a possible link between Aire and Treg cells. Abst.  European Congress of Immunology, Glasgow, Scotland, 5-8 September, 2012.
  112. N. Deshet-Unger, S. Hiram-Bab, Y. Ohana, M. Gross, M. C. Souroujon, M. Mittelman and D. Neumann. Benefits and Risks of Erythropoietin Treatment – Studies on the 5T33 Multiple Myeloma Mouse Model. Abst. Meeting on: Sensing Hypoxia in the Cell and the Organism, Essen, Germany, 20 - 23 September 2012.
  113. N. Deshet-Unger, S. Hiram-Bab, Y. Ohana, M. C. Souroujon, M. Mittelman  and D. Neumann. Erythropoietin treatment in multiple myeloma – a gentle balance.  Abst. 1st International Conference on Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging and Therapeutic Targets. Crete, Greece, October 4-9, 2012.
  114. Y. Haim Ohana, M. C. Souroujon, M. Gassmann, M. Mittelman and Drorit Neumann. Erythropoietin-associated increase in the proportion of Kupffer cells. Abst. 54th Annual meeting of the American Heart Society (ASH), Atlanta, GA, USA, December 8-11, 2012.
  115. R. Aricha, R. Aharoni, M. C. Souroujon, S. Berrih-Aknin and S. Fuchs. EAE and EAMG in Aire-/- mice: A link between Aire and Treg cells. Abst. 13th Annual meeting of the Israel Neuroimmunology Society. Jerusalem, December, 2012.
  116. N. Deshet-Unger, S. Hiram-Bab, Y. Ohana, M. Gross, M. C. Souroujon, Y. Gabet, M. Mittelman and D. Neumann. Erythropoietin treatment in multiple myeloma – friend and foe?  MPN&MPNr-EuroNet 7th meeting, Ohrid, Macedonia, April 24-26, 2013.
  117. J. M. Weiss, R. Aricha, M. Robinet, N. Dragin,  P. Cufi, F. Lantner, I. Shachar, M. C. Souroujon, S. Fuchs, S. Berrih-Aknin and R. Le Panse. Transgenic overexpression of CXCL13 in mouse thymus promotes B-cell recruitment and increases the susceptibility to experimental autoimmune myasthenia gravis. Myasthenia 2013. Paris July 1-3, 2013.
  118. R. Aricha, R. Aharoni, M. C. Souroujon, S. Berrih-Aknin and S. Fuchs. Age dependent course of EAMG and EAE in Aire-/- mice. Myasthenia 2013. Paris July 1-3, 2013.
Back

Other publications

A. Miller, M.C. Souroujon, F. Aloisi.
Translational neuroimmunology: A joint meeting of the Israel Society of Neuroimmunology and the Italian Neuroimmunology Association. Conference review. J Neuroimmunol. 216, 4-7, 2009.

Back

Open University Books (in Hebrew)

Introduction to Genetic Analysis (2012)

Immunology (2011) Immunology (1992) Virology (1995) Genetics - From Mendelism to Genetic Engineering (1990)

Back